



Canadian Journal of
Cardiology

Journal canadien
de cardiologie

www.onlinecjc.ca

Journal of the
Journal de la



Canadian
Cardiovascular
Society

Société
canadienne
de cardiologie

For Issue Highlights with article summaries, go to www.onlinecjc.ca.

Society Guidelines

249 The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization

Primary Panel: Gordon W. Moe, MD, MSc, FRCPC (Chair), Justin A. Ezekowitz, MB, BCh, MSc, FRCPC (Co-Chair), Eileen O'Meara, MD, FRCPC, Jonathan G. Howlett, MD, FRCPC, Steve E. Fremes, MD, FRCPC, Abdul Al-Hesayen, MD, FRCPC, George A. Heckman, MD, MSc, FRCPC, Anique Ducharme, MD, FRCPC, Estrellita Estrella-Holder, RN, BN, MScA, CCN(C), Adam Grzeslo, MD, CCFP, FCFP, Karen Harkness, RN, BScN, CCNC, PhD, Serge Lepage, MD, FRCPC, Michael McDonald, MD, FRCPC, Robert S. McKelvie, MD, FRCPC, Anil Nigam, MD, MSc, FRCPC, Miroslaw Rajda, MD, FRCPC, Vivek Rao, MD, PhD, FRCPC, Elizabeth Swiggum, MD, FRCPC, Sean Virani, MD, FRCPC, Vy Van Le, MD, FRCPC, Shelley Zieroth, MD, FRCPC, **Secondary Panel:** J. Malcolm O. Arnold, MD, FRCPC, Tom Ashton, MD, FRCPC, Michel D'Astous, MD, FRCPC, Paul Dorian, MD, FRCPC, Nadia Giannetti, MD, FRCPC, Haissam Haddad, MD, FRCPC, Debra L. Isaac, MD, FRCPC, Simon Kouz, MD, FRCPC, FACC, Marie-Hélène Leblanc, MD, FRCPC, Peter Liu, MD, FRCPC, Heather J. Ross, MD, FRCPC, Bruce Sussex, MD, FRCPC, and Michel White, MD, FRCPC

Publication Mail Agreement 41536048

Return undeliverable Canadian addresses to:

Trans continental Printing, 737 Moray St,
Winnipeg, MB R3J 3S9

Printed in Canada

COVER: Clinical determinants of decision-making factors when selecting medical vs surgical therapy for ischemia heart disease in heart-failure patients. From the article, "An Approach to the Rational Use of Revascularization in Heart Failure Patients" by Rouleau and Bonow, pages 281-287 of this issue.

Editorial

264 The Harbinger of Mortality in Heart Failure With Preserved Ejection Fraction: Do GDF-15 Levels Reflect Tandem, Deterministic Effects of Fibrosis and Inflammation?

Brendan N. Putko, BSc, Haran Yogasundaram, BSc, and Gavin Y. Oudit, MD, PhD

267 Role of Autoimmunity in Heart Disease: Is Chagas Heart Disease the Definitive Proof?

Brent A. McLean, BSc, and Gavin Y. Oudit, MD, PhD

270 Impaired Cardiac Function in Metabolic Syndrome

David Fitchett, MD, FRCP(C), and Kim A. Connelly, MBBS, PhD, FRACP

Point/Counterpoint

272 Heart Failure Clinics Are Still Useful (More Than Ever?)

Tiny Jaarsma, RN, PhD, and Anna Strömberg, RN, PhD

276 Specialist Heart Failure Clinics Must Evolve to Stay Relevant

Jonathan G. Howlett, MD, FRCPC, FACC

Continued

Table of Contents

Review

281 An Approach to the Rational Use of Revascularization in Heart Failure Patients

Jean L. Rouleau, MD, and Robert O. Bonow, MD

288 A Novel Approach to Drug Development in Heart Failure: Towards Personalized Medicine

Licette C.Y. Liu, MD, Adriaan A. Voors, MD, PhD, Mattia A.E. Valente, MD, and Peter van der Meer, MD, PhD

296 Destination Therapy With Left Ventricular Assist Devices: For Whom and When?

Liane F. Porepa, MD, and Randall C. Starling, MD, MPH

304 Conceptual Model for Heart Failure Disease Management

Efstathia Andrikopoulou, MD, Kariann Abbate, MD, and David J. Whellan, MD, MHS, FACC, FAHA

312 Risk Stratification in Acute Heart Failure

Douglas S. Lee, MD, PhD, and Justin A. Ezekowitz, MBCh, MSc

Brief Rapid Report

320 Left Ventricular Myocardial Dyssynchrony Is Already Present in Nondiabetic Patients With Metabolic Syndrome

Edward Crendal, Hons, Guillaume Walther, PhD, Fred Dutheil, PhD, MD, Daniel Courteix, PhD, Bruno Lesourd, PhD, MD, Robert Chapier, MD, Geraldine Naughton, PhD, Agnès Vinet, PhD, and Philippe Obert, PhD

Clinical Research

325 Effects of the Metabolic Syndrome on Right Heart Mechanics and Function

Marijana Tadic, MD, PhD, Cesare Cuspidi, MD, Aleksandra Slijivic, MD, Anita Andric, MD, Branislava Ivanovic, MD, PhD, Radisav Scepanovic, MD, PhD, Irena Ilic, MD, Ljilja Jozika, RN, Tamara Marjanovic, RN, and Vera Celic, MD, PhD

332 β I-Selective Adrenoceptor Antagonists Increase Plasma Levels of Anti-p2 β Antibodies and Decrease Cardiac Involvement in Chronic Progressive Chagas Heart Disease

Miguel H. Vicco, MD, Nazarena Pujato, BS, Iván Bontempi, BS, Luz Rodeles, MD, Iván Marcipar, PhD, and Oscar A. Bottasso, PhD, MD

338 Growth Differentiation Factor-15 Is a Useful Prognostic Marker in Patients With Heart Failure With Preserved Ejection Fraction

Yasuhiro Izumiya, MD, PhD, Shinsuke Hanatani, MD, Yuichi Kimura, MD, Seiji Takashio, MD, PhD, Eiichiro Yamamoto, MD, PhD, Hiroaki Kusaka, MD, Takanori Tokitsu, MD, Taku Rokutanda, MD, Satoshi Araki, MD, PhD, Kenichi Tsujita, MD, PhD, Tomoko Tanaka, MD, PhD, Megumi Yamamuro, MD, PhD, Sunao Kojima, MD, PhD, Shinji Tayama, MD, PhD, Koichi Kaikita, MD, PhD, Seiji Hokimoto, MD, PhD, and Hisao Ogawa, MD, PhD

345 QRS Widening Rates and Genetic Polymorphisms of Matrix Metalloproteinases in a Cohort of Patients With Chronic Heart Failure

Virgilio Olsen, MS, Luis E. Rohde, MD, PhD, Luis Beck-da-Silva, MD, PhD, Kátia G. Santos, PhD, Andréia Biolo, MD, PhD, Nadine Clausell, MD, PhD, and Michael Andrades, PhD

Table of Contents

352 Assessing the Burden of Hospitalized and Community-Care Heart Failure in Canada

Claudia Blais, PhD, Sulan Dai, MD, PhD, Chris Waters, BSc, Cynthia Robitaille, MSc, Mark Smith, MSc, Lawrence W. Svenson, BSc, Kim Reimer, BEd, BSc, Jill Casey, MSc, Rolf Puchtinger, MA, Helen Johansen, PhD, Yana Gurevich, MD, MPH, Lisa M. Lix, PhD, Hude Quan, MD, PhD, and Karen Tu, MD, MSc

Basic Research

359 Congenital Absence of Nitric Oxide Synthase 3 Potentiates Cardiac Dysfunction and Reduces Survival in Doxorubicin- and Trastuzumab-Mediated Cardiomyopathy

Matthew Zeglinski, BSc, MSc, Sheena Premecz, BSc, Jordyn Lerner, BSc, Piotr Wtorek, BSc, Megan daSilva, BSc, Devin Hasanally, BSc, Rakesh Chaudhary, PhD, Anita Sharma, PhD, James Thliveris, PhD, Amir Ravandi, MD, PhD, Pawan K. Singal, PhD, and Davinder S. Jassal, MD, FACC, FRCPC

368 Reduced Endoplasmic Reticulum Stress Might Alter the Course of Heart Failure Via Caspase-12 and JNK Pathways

Yu Liu, PhD, Jie Wang, MD, PhD, Shu-Ying Qi, PhD, Lei-Sheng Ru, PhD, Chao Ding, PhD, Hai-Jun Wang, PhD, Jing-Shan Zhao, MD, Jing-Jing Li, PhD, Ai-ying Li, PhD, and Dong-Mei Wang, MD

Letters to the Editor

376 Hypouricemic Effects of Prednisone and Allopurinol: An Uneven Playing Field?

Diluk R.W. Kannangara, BMedSc(Hons), Garry G. Graham, PhD, Kenneth M. Williams, PhD, and Richard O. Day, MD, FRACP

376 Reply to Day et al.—Hypouricemic Effect of Prednisone in Heart Failure: Possible Mechanisms

Chao Liu, MD, and Kunshen Liu, MD

Departments

A10 Information for Readers

A12 Announcement: Focus Issue on The Obesity Epidemic: Implications and Approaches